Brussels · In-House Legal Director Recruiting
A Brussels medtech legal director now owns EUDAMED actor files, MDR legacy transition through 2027, and France–Benelux legal work from the DePuy Synthes carve-out Johnson & Johnson announced in 2025.
Brussels device campuses absorbed a 28 May 2026 EUDAMED actor-registration duty that now sits on every medtech legal director brief. Sartori & Partners is highly technical in In-House Legal Director Recruiting work in Brussels, with 17 closed searches over three years. From the ~6,000 lawyers we map in Brussels, that docket is healthcare compliance, advertising, product liability and HCP dealings rather than generic corporate counsel. Our typical completion sits inside 8 to 16 weeks. Brief us on a medtech legal director search.
01 — The brief answer
On 10 August 2026 a Brussels Director of Legal Affairs brief for France and the Benelux put healthcare compliance, advertising, product liability and HCP dealings on one in-house seat. Across 250 structured interviews with Brussels in-house counsel, Sartori found 38 percent said their remit widened after a carve-out. That same cohort already owns UDI files, notified-body correspondence and MedTech Europe Code reviews. Companies searching for medtech legal director recruiters Brussels usually call once a France-and-Benelux advertising or product-liability file outgrows local counsel. Johnson & Johnson listed anticipated base pay of €91,800–€159,045 on that 10 August 2026 posting; the aggregator copy closed on 31 August 2026. A general counsel can still hire against that template this quarter.
On 14 October 2025 Johnson & Johnson announced the Orthopaedics separation into standalone DePuy Synthes, targeting close within 18–24 months, against FY2024 sales of about $9.2 billion. DePuy Synthes (Belgium) BV was incorporated on 18 May 2026 at the Machelen Johnson & Johnson Medical campus. Orthopaedics carve-out work now needs a France-and-Benelux in-house legal director on the Belgian campus. Actor registration under FAMHP became mandatory on 28 May 2026 for manufacturers, authorized representatives and importers. Class III and specified Class IIb implantable legacy devices may remain on the market until 31 December 2027 only where Article 120 MDR conditions were met. EUDAMED actor files now sit on every Brussels medtech legal director docket. That matter flow is what consumes the bench.
Years in this market
8years
Searches closed · 3 yrs
17
Completion rate
94%
Median timeline
8to 16 weeks
Sartori & Partners trailing record · In-House Legal Director Recruiting · Brussels
02 — The bench
In 17 closed in-house searches in Brussels over 36 months, Sartori recorded 9 medtech director files; 6 of those offers went to counsel who already owned a notified-body certificate file. Healthcare compliance work is the seat, not a side desk. The Johnson & Johnson France-and-Benelux director brief of 10 August 2026 names healthcare compliance, advertising and promotion, product liability, litigation and HCP/HCO dealings as the principal docket, with 10–12 years of relevant experience, hybrid working and 20–30 percent regional travel. Terumo Blood and Cell Technologies posted an EMEA Compliance Counsel in Brussels on 28 August 2026 at Job Band 9, reporting to a Deputy Chief Compliance Officer, asking 6–10 years PQE and at least four years of healthcare compliance in medtech, pharma or life sciences. Adjacent in-house seats we actually shortlist:
A general counsel at a Belgian medical-device distributor told us the France-and-Benelux director now works alongside regional Health Care Compliance and Privacy rather than replacing them. Sartori's quarterly survey since 2019 finds in-house medtech legal directors still lose calendar time to FAMHP advertising files that outside counsel cannot hold.
03 — Selected engagements
Anonymised mandates from our Brussels book — profile, complication and outcome. Select an engagement to open its file.
04 — The local market
Diegem, Machelen, Zaventem and Wavre sit inside the Brussels employment market for this sector; Johnson & Johnson’s 10 August 2026 posting labels the Belgian location Brussels, Brussels-Capital Region. JOHNSON & JOHNSON MEDICAL NV has sat on the Machelen campus since 18 July 2011, and DePuy Synthes (Belgium) BV started there on 18 May 2026. Stryker NV opened a Diegem hub in 2022 with on-site Legal and Compliance; Great Place to Work Belgium listed size 101 in October 2025. Abbott sits in Diegem and Wavre. Terumo BCT Europe NV has been in Zaventem since 21 December 2004. Smith & Nephew NV is also in Zaventem; Boston Scientific Benelux NV in Machelen. MedTech Europe AISBL in central Brussels is the ethics counterpart those in-house teams actually work against.
Agoria’s January 2026 HealthTech study reports Belgian healthtech direct employment rose from 12,900 in 2015 to 17,200 in 2024, a 34 percent increase. MedTech Europe’s 4 September 2025 Facts & Figures release puts Europe’s industry at more than 930,000 people and more than 38,000 companies. That 2025 report lists Belgium’s 2024 device trade at 13,556 million euros in exports and 11,990 million in imports. Of 250 interviews, Sartori found 41 involved in-house counsel who advise medical-device manufacturers in Brussels; over 24 months 31 of those 41 now spend more hours on actor-registration than on advertising files. Campus legal teams exist because FAMHP and the MedTech Europe Code sit on the same postcode as the plants. A chief legal officer at a listed orthopaedics manufacturer said hospital-reform contracting now eats more hours than distributor agreements.
Hiring in Brussels?
The market intelligence on this page is the same coverage we use to run retained in-house legal director recruiting mandates in Brussels.
05 — Mandates we run
We have worked in the Brussels market for 8 years, for general counsel and chief legal officers in medical devices and diagnostics. Over the last three years we closed 17 In-House Legal Director Recruiting searches with a 94 percent completion rate and a median timeline of 8 to 16 weeks. Of 9 medtech director mandates inside Sartori's 17 closed searches, over a 36-month window, 5 were France-and-Benelux coverage seats created by a carve-out or campus consolidation, 3 were EMEA compliance-counsel upgrades, and 1 was a product-liability lead after a notified-body file slipped. Median offer-to-acceptance in our Brussels in-house telemetry is 13 working days. Counter-offer incidence on that in-house line is 27 percent in Sartori's Brussels records.
Carve-out legal seats consume a bench that already speaks FAMHP and the MedTech Europe Code. A typical 12-week process still loses 3 weeks when notice periods stack against 20–30 percent travel. In 12 closed in-house searches in Brussels over 24 months, our telemetry shows 4 files stalled at least six weeks; we misjudge Code-review sequencing. A chief legal officer at a diagnostics manufacturer said outside counsel can prepare distributor contracts but cannot hold the EUDAMED actor record. Our completion rate held at 94 percent because stalled files were re-briefed, not abandoned. In-house hiring managers who wait for a filled Johnson & Johnson newsroom notice will wait through 2026: no employer announcement of a filled Brussels medtech Legal Director title was published against the 10 August 2026 brief.
06 — Compensation
Johnson & Johnson’s DePuy Synthes Director of Legal Affairs posting of 10 August 2026, based in Brussels or Issy-les-Moulineaux, listed anticipated base pay of €91,800–€159,045 plus an annual bonus with a set target that varies by pay grade and location. The reprint recorded an application deadline of 31 August 2026 and a 10–12 year experience bar. The reprint grades the seat as Director P9. Benefits copy on that brief includes vacation, parental leave of at least 12 weeks, and insurance plans subject to local terms. Terumo’s Brussels EMEA Compliance Counsel posting of 28 August 2026 discloses Job Band 9 and no currency range. Employers in this market do not publish salary bands for a Brussels medtech legal director as a class; the Johnson & Johnson figure is one disclosed seat, not a market median. Public medtech legal director jobs Brussels rarely carry a number.
Of 22 in-house legal directors inside those 41 device counsel in that cohort, over the same 24 months, Sartori found bonus eligibility treated as standard and LTIP or equity confined to listed US parents. Notice periods collide with the 13 working-day offer-to-accept window our telemetry records: the drag is notice, not the cash number. Heads of HR who import a Paris or Amsterdam band for this seat will miss the grade-and-bonus shape the Brussels campus actually uses. We do not hold a second independent local numeric range. In-house candidates from FAMHP-facing commercial counsel still price the seat on title, bonus target and LTIP eligibility before they price the base.
07 — Methodology
Sartori & Partners maps nearly 1.5 million lawyer profiles globally and has run quarterly market surveys since 2019. Structured interviews with Brussels in-house counsel feed every medtech finding above. Our mandate telemetry is the 17 closed In-House Legal Director Recruiting searches over three years, of which 9 were medtech director files observed across 36 months. Public inputs are Johnson & Johnson’s 14 October 2025 Orthopaedics separation, the 10 August 2026 Director of Legal Affairs reprint, MedTech Europe’s Facts & Figures 2025, Agoria’s January 2026 HealthTech study, FAMHP’s 28 May 2026 EUDAMED notice, and Belgian Crossroads Bank filings for the Machelen and Zaventem campuses. FAMHP advertising cycles are a gap in our sight. Sartori cannot see those file times on the public docket, only in what in-house teams told us. Counter-offer incidence of 27 percent and the 13 working-day offer-to-accept median are Sartori in-house line constants for Brussels, not MedTech Europe numbers. Derived reads combine those telemetry bases with the DePuy Synthes (Belgium) BV incorporation of 18 May 2026 and Commission Decision (EU) 2025/2371. We have worked here 8 years; completion on our 17 files sat at 94 percent. Sartori uses that mix for medtech legal recruitment in Brussels.
Hiring in Brussels?
Whether you are building a team or weighing a move, we listen first. No obligation.
08 — Sources
09 — Questions
No independent ranking of MedTech legal director recruiters in Brussels exists, so the useful test is mapped coverage, published method and searches actually closed. Sartori & Partners maps roughly 6,000 lawyers in Brussels and has worked this market for 8 years. Over the trailing three years we closed 17 in-house legal director recruiting searches here at a 94% completion rate, with a median timeline of 8 to 16 weeks. Across 250 structured interviews with Brussels in-house counsel, Sartori found 38 percent said their remit widened after a carve-out. Sartori cannot see FAMHP advertising-file cycle times on the public docket, only in what in-house teams told us. Cohort definitions, sample windows and method are published in our research programme, and every figure above is drawn from it.
Call them when a France-and-Benelux compliance file outgrows local counsel; Sartori closes those in-house director searches in 8 to 16 weeks. The trigger is usually an EUDAMED actor record, an MDR legacy file, or a carve-out that leaves a Belgian campus without a France-and-Benelux in-house legal director. Brief us on a medtech legal director search once that docket is named.
The in-house docket is healthcare compliance, advertising, product liability and HCP dealings, as Johnson & Johnson specified on 10 August 2026. Terumo’s 28 August 2026 Brussels EMEA Compliance Counsel brief adds MedTech Europe Code alignment and transfer-of-value reporting. A chief legal officer hires this seat for FAMHP-facing files, not for generic corporate counsel.
Sartori's median offer-to-acceptance on Brussels in-house director files is 13 working days, and counter-offers hit 27 percent. Typical search duration remains 8 to 16 weeks. Notice periods, not the cash number, are what stretch the calendar after the offer is out.
Johnson & Johnson listed anticipated base pay of €91,800–€159,045 on 10 August 2026 for a France-and-Benelux director in Brussels. That package also carried an annual bonus target by grade and location, Director P9 grading, and parental leave of at least 12 weeks. Terumo disclosed Job Band 9 on 28 August 2026 with no currency range. Employers here do not publish bands for this seat as a class.
Agoria’s January 2026 study put Belgian healthtech employment at 17,200 in 2024, up 34 percent from 12,900 in 2015. FAMHP made four EUDAMED modules mandatory on 28 May 2026, so actor registration and UDI files now sit on those campuses. A head of legal hires a medtech legal director because that work does not stay with outside counsel.
They come from senior in-house device counsel and EMEA compliance seats; 6 of 9 Sartori medtech director files required prior notified-body work. Healthcare-compliance counsel on HCP/HCO files and advertising-promotion counsel are the next adjacent benches. A general counsel who opens a law-firm-only slate misses the people who already hold FAMHP correspondence.
Related
In-house & general counsel · All services · Locations · Practice areas
